Oncoinvent ASA (OSL:ONCIN) Total Current Liabilities: kr57.96 Mil (As of Dec. 2025)


OSL:ONCIN Oncoinvent ASA OSL:ONCIN
37 GF Score
Price kr66.00
GF Value kr973.15
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Oncoinvent ASA Total Current Liabilities?

Oncoinvent ASA OSL:ONCIN +14.58% 37 Total Current Liabilities is kr57.96 Mil as of Dec. 2025. GuruFocus rates OSL:ONCIN with a GF Score™ of 37/100 and a GF Value™ of kr973.15 (Possible Value Trap). The stock has 4 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Oncoinvent ASA's total current liabilities for the quarter that ended in Dec. 2025 was kr57.96

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Oncoinvent ASA Total Current Liabilities Related Terms

Oncoinvent ASA Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Oncoinvent ASA's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncoinvent ASA Total Current Liabilities Chart

Oncoinvent ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 64.87 77.93 46.86 57.94 57.96

Oncoinvent ASA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.86 43.21 57.94 19.75 57.96
OSL:ONCIN
37GF Score
Oncoinvent ASA OSL:ONCIN
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncoinvent ASA Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Oncoinvent ASA's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=21.218+2.875
+Other Current Liabilities+Current Deferred Liabilities
=33.866+0
=57.96

Oncoinvent ASA's Total Current Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=21.218+2.875
+Other Current Liabilities+Current Deferred Liabilities
=33.866+0
=57.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of kr57.96 Mil mean?
Oncoinvent ASA (OSL:ONCIN) has a Total Current Liabilities of kr57.96 Mil as of Dec. 2025. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Oncoinvent ASA and its competitors.
Is Oncoinvent ASA's Total Current Liabilities too high?
Oncoinvent ASA's current Total Current Liabilities is kr57.96 Mil. Overall, Oncoinvent ASA has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncoinvent ASA's Total Current Liabilities compare to VRTX and REGN?
Oncoinvent ASA's Total Current Liabilities of kr57.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Oncoinvent ASA and its competitors. Oncoinvent ASA's current Total Current Liabilities is kr57.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoinvent ASA stock overvalued right now?
Based on GuruFocus' analysis, Oncoinvent ASA (OSL:ONCIN) is currently considered Possible Value Trap. The stock's GF Value™ is kr973.15, compared to a current price of kr66.00 — trading 93.2% below its estimated fair value. The current Total Current Liabilities is kr57.96 Mil. Oncoinvent ASA's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Oncoinvent ASA (OSL:ONCIN), the current Total Current Liabilities is kr57.96 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncoinvent ASA (OSL:ONCIN) Overvalued in 2026?

Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued. The current stock price of kr66.00 is trading 93.2% below its estimated GF Value™ of kr973.15. GuruFocus considers Oncoinvent ASA to be Possible Value Trap.

Key valuation signals for OSL:ONCIN:

  • Total Current Liabilities: kr57.96 Mil
  • GF Value™: kr973.15 vs. price of kr66.00 (93.2% below fair value)
  • GF Score™: 37/100 with 4 warning signs

No single metric tells the full story. See the OSL:ONCIN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncoinvent ASA Business Description

Other Exchanges 0RU5:UK7BG:Germany
Address Gullhaugveien 7, Oslo, NOR, 0484
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
37GF Score

Get the complete analysis for OSL:ONCIN

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr66.00
Price
kr973.15
GF Value